Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy
dc.contributor.author | Robertson, Patricia L. | en_US |
dc.contributor.author | DaRosso, Robert C. | en_US |
dc.contributor.author | Allen, Jeffrey C. | en_US |
dc.date.accessioned | 2006-09-11T15:59:52Z | |
dc.date.available | 2006-09-11T15:59:52Z | |
dc.date.issued | 1997-03 | en_US |
dc.identifier.citation | Robertson, Patricia L.; DaRosso, Robert C.; Allen, Jeffrey C.; (1997). "Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy." Journal of Neuro-Oncology 32(1): 71-80. <http://hdl.handle.net/2027.42/45385> | en_US |
dc.identifier.issn | 1573-7373 | en_US |
dc.identifier.issn | 0167-594X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45385 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=9049865&dopt=citation | en_US |
dc.description.abstract | The 5 year survival for patients with malignant intracranial non-germinoma germ cell tumors (NGGCT) which include endodermalsinus tumors, embryonal carcinomas, choriocarcinomas and immatureteratomas is less than 25% following a small resection and radiotherapy. In an effort to improve the survival of these patients, an approach using an attempt at radical resection wherefeasible, followed by multi-modality ’sandwich‘ therapy (chemotherapy-radiation-chemotherapy) was used to treat 18 newly diagnosed patients between 1986 and 1994 in a multi-institution study. Fourteen patients had histologically proven NGGCT andfour were presumed NGGCT because of markedly elevated concentrations of serum and/or CSF alpha fetoprotein (AFP) and/or beta human chorionic gonadatrophin (b-HCG). The primary tumor was confined to thepineal region in 12 patients, the suprasellar region in five, and acerebral hemisphere in one. None of the patients had central nervoussystem metastases at diagnosis by MRI imaging of the spine and CSF cytology. Radical surgical resection was performedinitially in 11 patients (gross total — 6, subtotal — 5);four had a biopsy and three had no surgery. All patients then received3 or 4 cycles of neoadjuvant chemotherapy with cisplatin (100 mg/m 2 /cycle) and VP-16 (500 mg/m 2 /cycle)/cycle). Of the 12 patients with evaluabledisease there were 9 responses to the neoadjuvant chemotherapy (5 CR,4 PR); 2 patients had stable disease and 1 progressed duringchemotherapy. Six patients with no evaluable disease after a grosstotal resection had a continuous complete response. Seventeen patientsreceived radiation therapy (involved field — 11, involved field + craniospinal — 4, involved field+ whole brain — 2). Twelve patients received 4 cycles post-radiation chemotherapy with vinblastine (6.5 mg/m 2 /cycle), bleomycin (15 U/m 2 /cycle),VP-16 (300 mg/m 2 /cycle, carboplatin (450 mg/m 2 /cycle). A total of four patients have died (3 — progressive/recurrent disease, 1 — metabolic). Four year actuarialevent-free and total survival rates are 67% and 74%. This multi-modality adjuvant therapy approach appears to dramatically improve the outcome of malignant intracranialNGGCT. | en_US |
dc.format.extent | 67180 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Radiotherapy | en_US |
dc.subject.other | Brain Neoplasm | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Germ Cell Tumor | en_US |
dc.subject.other | Chemotherapy | en_US |
dc.title | Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Ophthalmology | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Pediatrics and Neurology, University of Michigan Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Neurology, USA; the Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY | en_US |
dc.contributor.affiliationother | Department of Neurology, USA; the Kaplan Comprehensive Cancer Center, New York University Medical Center, New York, NY | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 9049865 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45385/1/11060_2004_Article_110512.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1005732105727 | en_US |
dc.identifier.source | Journal of Neuro-Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.